POSC321 Estimating Long-Term Survivorship Rates for Previously Untreated Intermediate or Poor (I/P) Risk Advanced Renal Cell Carcinoma (ARCC) Patients Treated with Nivolumab Plus Ipilimumab (NIVO+IPI): Analyses from the CheckMate 214 Trial

V Paly, S. George, J. H. Youn,J. Borrill,F. Ejzykowicz,J. R. May,M. Kurt

Value in health（2022）

引用 0|浏览5

暂无评分

摘要

This analysis aimed to explore survival heterogeneity and estimate proportion of potential long-term survivors (LTS) among previously untreated, I/P risk aRCC patients who received immune-checkpoint inhibitors (ICIs) NIVO+IPI in the CheckMate 214 trial by applying mixture cure models (MCMs).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要